Published in Lancet on July 07, 2012
Mass gatherings and mass gatherings health. Saudi Med J (2016) 0.75
Current trends and newer concepts on diagnosis, management and prevention of respiratory tract infections. Curr Opin Pulm Med (2013) 0.75
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Global health 2035: a world converging within a generation. Lancet (2013) 16.85
Priority actions for the non-communicable disease crisis. Lancet (2011) 15.18
Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med (2004) 14.78
Clinical trial registration: a statement from the International Committee of Medical Journal Editors. JAMA (2004) 14.17
Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med (2013) 11.85
Clinical trial registration: a statement from the International Committee of Medical Journal Editors. CMAJ (2004) 8.52
Chronic diseases: global action must match global evidence. Lancet (2010) 7.52
Putting clinical trials into context. Lancet (2005) 7.29
Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Lancet (2004) 7.18
Validation of housekeeping genes for normalizing RNA expression in real-time PCR. Biotechniques (2004) 6.42
Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis (2013) 6.14
Health research in the UK: the price of success. Lancet (2006) 5.14
Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis (2010) 5.14
Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Ann Intern Med (2004) 5.06
Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol (2013) 4.98
Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet (2010) 4.95
Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg Infect Dis (2013) 4.78
Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet (2010) 4.71
Accurate and rapid identification of bacterial species from positive blood cultures with a DNA-based microarray platform: an observational study. Lancet (2009) 4.53
Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis (2009) 4.14
Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis (2013) 4.08
Clinical trial registration--looking back and moving ahead. N Engl J Med (2007) 4.07
Transmission of MERS-coronavirus in household contacts. N Engl J Med (2014) 3.81
UN High-Level Meeting on Non-Communicable Diseases: addressing four questions. Lancet (2011) 3.68
Is this clinical trial fully registered?--A statement from the International Committee of Medical Journal Editors. N Engl J Med (2005) 3.44
Intensive versus conventional insulin therapy: a randomized controlled trial in medical and surgical critically ill patients. Crit Care Med (2008) 3.40
Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013. Emerg Infect Dis (2014) 3.25
Health risks at the Hajj. Lancet (2006) 3.18
Modernising medical careers, medical training application service, and the postgraduate medical education and training board: time for the emperors to don their clothes. Lancet (2007) 3.12
Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis (2013) 3.12
Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J Infect Dis (2012) 3.09
Rift Valley fever: an uninvited zoonosis in the Arabian peninsula. Int J Antimicrob Agents (2003) 2.96
Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet (2002) 2.92
A manifesto for maternal health post-2015. Lancet (2013) 2.91
Immunological biomarkers of tuberculosis. Nat Rev Immunol (2011) 2.88
Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet (2012) 2.83
Research challenges to improve maternal and child survival. Lancet (2007) 2.80
A call to action for the new decade of vaccines. Lancet (2011) 2.72
Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ (2008) 2.66
Use of dried whole blood spots to measure CD4+ lymphocyte counts in HIV-1-infected patients. Lancet (2003) 2.64
Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J (2012) 2.61
Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med (2007) 2.58
Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med (2009) 2.55
Measuring progress on NCDs: one goal and five targets. Lancet (2012) 2.55
Why are 4 million newborn babies dying each year? Lancet (2004) 2.50
Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus. MBio (2014) 2.50
Uniform format for disclosure of competing interests in ICMJE journals. N Engl J Med (2009) 2.46
Public health in the new era: improving health through collective action. Lancet (2004) 2.45
Offline: Lessons from the controversy over statins. Lancet (2016) 2.43
Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay--a clinical validation study. PLoS One (2011) 2.40
Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS (2005) 2.38
Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study. Lancet Infect Dis (2012) 2.29
Counting for health. Lancet (2007) 2.21
Non-travel-associated hepatitis E in England and Wales: demographic, clinical, and molecular epidemiological characteristics. J Infect Dis (2005) 2.18
Progress towards improved tuberculosis diagnostics for developing countries. Lancet (2006) 2.16
Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis (2013) 2.16
Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. Lancet (2005) 2.15
Education of health professionals for the 21st century: a global independent Commission. Lancet (2010) 2.10
Investigation of anti-middle East respiratory syndrome antibodies in blood donors and slaughterhouse workers in Jeddah and Makkah, Saudi Arabia, fall 2012. J Infect Dis (2013) 2.06
Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect Dis (2013) 2.05
A renewed agenda for global mental health. Lancet (2011) 2.04
Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples. PLoS One (2010) 2.03
Tuberculosis--time to accelerate progress. Lancet (2010) 2.03
Global public health implications of a mass gathering in Mecca, Saudi Arabia during the midst of an influenza pandemic. J Travel Med (2010) 2.00
Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol (2006) 1.99
Global perspectives for prevention of infectious diseases associated with mass gatherings. Lancet Infect Dis (2012) 1.99
Clinical trial registration. BMJ (2007) 1.95
Prevention of influenza at Hajj: applications for mass gatherings. J R Soc Med (2013) 1.95
Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis (2012) 1.89
Clinical trial registration: looking back and moving ahead. Croat Med J (2007) 1.89
A family cluster of Middle East Respiratory Syndrome Coronavirus infections related to a likely unrecognized asymptomatic or mild case. Int J Infect Dis (2013) 1.88
Middle East respiratory syndrome coronavirus infections in health care workers. N Engl J Med (2013) 1.87
Influenza a common viral infection among Hajj pilgrims: time for routine surveillance and vaccination. J Travel Med (2004) 1.85
Brazil: towards sustainability and equity in health. Lancet (2011) 1.85
The Darzi vision: quality, engagement, and professionalism. Lancet (2008) 1.79
Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. CMAJ (2005) 1.78
The Lancet-University of Oslo Commission on Global Governance for Health, in collaboration with the Harvard Global Health Institute. Lancet (2011) 1.78
Righting the balance: energy for health. Lancet (2007) 1.76
Urine for the diagnosis of tuberculosis: current approaches, clinical applicability, and new developments. Curr Opin Pulm Med (2010) 1.73
Immune responses to tuberculosis in developing countries: implications for new vaccines. Nat Rev Immunol (2005) 1.72
Rethinking our approach to physical activity. Lancet (2012) 1.72
Lung remodeling in pulmonary tuberculosis. J Infect Dis (2005) 1.71
Clinical trial registration: looking back and moving ahead. Ann Intern Med (2007) 1.71
Severe acute respiratory syndrome vs. the Middle East respiratory syndrome. Curr Opin Pulm Med (2014) 1.69
Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Lancet (2010) 1.69
The critically ill avian influenza A (H5N1) patient. Crit Care Med (2007) 1.65
Doctors and climate change. BMJ (2007) 1.65
Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. JAMA (2005) 1.65